OFF-MARKET-Medical Device Company For Major Heart Surgery for Sale

OFF-MARKET ‘Q3 2024

Life Saving Medical Device Company For Major Heart Surgery

New York, NY

Seller financing may be available if the price and deal structure is right.

Asking Price: Best Possible Offer

Cash Flow $31,405

Gross Revenue: $169,210

EBITDA: N/A

FF&E: N/A

Inventory: N/A

Established: 1998

Business Description

Detailed Information

Our client is offering the sale of the patent and rights and current royalties stream of income to a lifesaving, ready to use device which lowers mortality, stroke risk and other risk factors in Transcatheter Aortic Valve Implantation (TAVI) or transcatheter aortic valve replacement (TAVR) procedures.

The patented device available for rights and royalties stream revenue purchase can simply be added to existent equipment to immediately improve patient outcomes. It was developed by a renowned M.D. and professor, a prolific inventor who owns more than 20 issued US and tens of International Patents and a similar number of pending patents.

According to the developer “The vision of our Project (was) to significantly improve the safety of TAVI/TAVR. Integrating or adding-on an active double-filtering, emboli capturing,
collecting and removal component to the TAVI/TAVR procedure is a breakthrough. With our approach, we are bringing a better solution than the currently used deflective anti-embolic devices for preventing cerebral embolic complications. “As such, our device can be developed in 3 versions:

• Integrated to the existing delivery system
• As an add-on to an existing delivery system (generic – to fit all delivery systems)
• Independent system, inserted contra-laterally to the TAVI/TAVR delivery system

(Our client) think(s) that by avoiding secondary procedures as much as possible and by adding better filtering, entrapping, and removing embolic material as with (our client’s) device, not only “silent strokes” but other “silent vascular complications” also can be prevented. (Our client) believe(s) that the use of intra-procedural emboli protection is the best approach to reduce intra- and post-procedural embolic complications”.

NDA is required {SUBMIT BELOW} to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Facilities:

N/A – Relocatable worldwide.

Growth & Expansion:

Our client tells us that “The number of TAVI/TAVR procedures all over the world has increased exponentially in recent years. About 75,000 Aortic Valve Replacements are performed annually worldwide. (TAVIinformation.com) The current number of patients eligible for TAVI/TAVR procedures is approximately 350.000 worldwide, a number that is expected to grow considerably in the future.”

Financing: If the price and deal structure is right.

Support & Training:

As needed – specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business.

Reason for Selling:

Other business interests.